Abstract | BACKGROUND AND AIM: Reflux symptoms in patients with non-erosive reflux disease (NERD) cannot be easily controlled by treatment with proton pump inhibitors (PPI). The anti-inflammatory function of rebamipide may be effective for protecting the esophageal mucosa. This prospective randomized multicenter placebo-controlled study was performed to clarify the efficacy of rebamipide for NERD patients whose reflux symptoms were refractory to PPI treatment. METHODS: One hundred forty-nine patients were enrolled on the basis of a QUEST score of over 6 and absence of endoscopically proven esophageal mucosal breaks. All the patients were initially administered 15 mg of lansoprazole for 4 weeks, and the symptoms were then assessed using QUEST and GSRS. PPI-refractory patients were randomly assigned to administration of rebamipide or placebo t.i.d. for 4 weeks. RESULTS: Three of the 149 patients were lost to follow-up, and 60 among the remaining 146 patients were found to be PPI-refractory. Among these PPI-refractory patients, 31 were randomly assigned to a rebamipide group and 29 to a placebo group. At the end of drug administration, the QUEST and GSRS scores did not differ between the rebamipide and placebo groups, although a significantly higher proportion of patients in the rebamipide group showed amelioration of abdominal pain and diarrhea. CONCLUSION: Administration of rebamipide cannot effectively control reflux symptoms in NERD patients whose symptoms are refractory to PPI therapy.
|
Authors | Kyoichi Adachi, Kenji Furuta, Hiroto Miwa, Tadayuki Oshima, Masaharu Miki, Yoshinori Komazawa, Katsuhiko Iwakiri, Takahisa Furuta, Tomoyuki Koike, Tomohiko Shimatani, Yoshikazu Kinoshita |
Journal | Digestive diseases and sciences
(Dig Dis Sci)
Vol. 57
Issue 6
Pg. 1609-17
(Jun 2012)
ISSN: 1573-2568 [Electronic] United States |
PMID | 22367114
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Proton Pump Inhibitors
- Quinolones
- Lansoprazole
- rebamipide
- Alanine
|
Topics |
- 2-Pyridinylmethylsulfinylbenzimidazoles
(adverse effects, therapeutic use)
- Adult
- Aged
- Aged, 80 and over
- Alanine
(analogs & derivatives, therapeutic use)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Resistance
- Esophageal pH Monitoring
- Esophagoscopy
(methods)
- Female
- Follow-Up Studies
- Gastroesophageal Reflux
(diagnosis, drug therapy)
- Humans
- Lansoprazole
- Male
- Middle Aged
- Prospective Studies
- Proton Pump Inhibitors
(adverse effects, therapeutic use)
- Quinolones
(therapeutic use)
- Recurrence
- Reference Values
- Risk Assessment
- Severity of Illness Index
- Statistics, Nonparametric
- Treatment Outcome
- Young Adult
|